beta
Trial Radar IA
Lo studio clinico NCT05734794 (STORM) per Sindrome nefrosica nei bambini, Rituximab è in arruolamento. Consulti la vista a schede del Radar degli Studi Clinici e gli strumenti di scoperta IA per tutti i dettagli. Oppure, ponga pure una domanda qui.
Un studio corrisponde ai criteri del filtro
Vista a schede
Torna alla ricerca

Study of Rituximab Monotherapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial (STORM) Fase III 80 Randomizzato

In arruolamento
I dettagli dello studio clinico sono disponibili principalmente in inglese. Tuttavia, Trial Radar IA può essere d'aiuto! Basta cliccare su 'Spiega lo studio' per visualizzare e discutere le informazioni sullo studio nella lingua selezionata.
La sperimentazione clinica NCT05734794 (STORM) è uno studio interventistico di Fase III volto a esaminare il trattamento per Sindrome nefrosica nei bambini, Rituximab, attualmente in arruolamento. Avviato il 9 febbraio 2023, prevede di arruolare 80 partecipanti. Sotto la guida di The Children's Hospital of Zhejiang University School of Medicine, dovrebbe concludersi entro il 30 luglio 2026. I dati più recenti da ClinicalTrials.gov sono stati aggiornati l'ultima volta il 25 agosto 2023.
Sommario breve
The main objective is to evaluate the effectiveness of Rituximab monotherapy versus steroid therapy on children with new-onset nephrotic syndrome within the 52-week follow-up.
Descrizione dettagliata
Nephrotic syndrome(NS) -------the most common glomerular disease in children. Steroid, as the mainstream therapy for decades, many patients suffer from adverse effects of it, such as growth impacted, fat, and glaucoma.There is a urgent need for Steroid-sparing therapy. Rituximab, as a chemical monoclonal antibody against the cluster of differentiation antigen 20(CD20), has proved to be effective in patients with freq...Mostra di più
Titolo ufficiale

Study of Rituximab Monotherapy VS Steroid Therapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial

Patologie
Sindrome nefrosica nei bambiniRituximab
Pubblicazioni
Articoli scientifici e documenti di ricerca pubblicati su questo studio clinico:
Altri ID dello studio
  • STORM
Numero NCT
NCT05734794
Data di inizio (effettiva)
2023-02-09
Ultimo aggiornamento pubblicato
2023-08-25
Data di completamento (stimata)
2026-07-30
Arruolamento (previsto)
80
Tipo di studio
Interventistico
FASE
Fase III
Stato
In arruolamento
Parole chiave
Rituximab
Glucocorticosteroids
Scopo principale
Trattamento
Allocazione
Randomizzato
Modello di intervento
In parallelo
Mascheramento
Nessuno (studio in aperto)
Bracci / Interventi
Gruppo/Braccio di partecipantiIntervento/Trattamento
SperimentaleRituximab Group
Rituximab dose: 4 doses of 375 mg/m2 rituximab at 1-week intervals( within +7 days).
Rituximab
Rituximab dose: 4 doses of 375 mg/m2 rituximab at 1-week intervals( within +7 days), associated with trimethoprim-sulfamethoxazole(25-50 mg/kg/day orally twice per day, 3 days per week. If the patient is not allergic) for three months from the first rituximab dosing date(Day 1). Four doses of rituximab are necessary whether the patient achieves complete remission.
Comparatore attivoSteroid Group
Daily oral prednisone/prednisolone 2 mg/kg/d (maximum 60 mg/d) for 6 weeks followed by alternate day prednisone/prednisolone, 1.5 mg/kg (maximum of 50 mg), for other 6 weeks.
Steroid
Daily oral prednisone/prednisolone 2 mg/kg/d (maximum 60 mg/d) for 6 weeks followed by alternate day prednisone/prednisolone, 1.5 mg/kg (maximum of 50 mg), for other 6 weeks. Vitamin D and calcium(adjusted according to the blood calcium level) were administered for three months.
Esito primario
Misure di esitoDescrizione della misuraArco temporale
Recurrence-free survival time(day) after first complete remission
The time from complete remission to the first relapse during the whole 52-week follow-up in patients who achieve complete remission within 6 weeks. In order to evaluate the remission, all the participants will document their proteinuria. Relapse is defined by first-morning urine dipstick ≥3+ on three or more consecutive days, 24-h PCR≥2.0g/g, or 24-h urine protein ≥ 50mg/kg, with or without edema after complete remission(KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases). Complete remission is defined by the first morning or 24h PCR ≤ 0.2g/g (or negative or trace dipstick) on three or more consecutive occasions(KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases).
From complete remission to 52 weeks
Esito secondario
Misure di esitoDescrizione della misuraArco temporale
Complete remission of nephrotic syndrome
Complete remission is defined by the first morning or 24h PCR ≤ 0.2g/g (or negative or trace dipstick) on three or more consecutive occasions (KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases). It will be recorded as "1" when patients achieve complete remission, or as "0".
From admission day to 6 weeks
Inefficiency of nephrotic syndrome
Inefficiency is defined as patients still have nephrotic-range proteinuria(first-morning urine dipstick ≥3+dipstick, 24-h PCR≥2.0g/g, or 24-h urine protein ≥ 50mg/kg) after 6-week treatment.
From admission day to 6 weeks
The time(day) to first complete remission
The time(day) from the first medicine administration to complete remission within 6 weeks.Complete remission is defined by the first morning or 24h PCR ≤ 0.2g/g (or negative or trace dipstick) on three or more consecutive occasions (KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases).
From admission day to 6 weeks
Relapse of nephrotic syndrome
Relapse is defined as patients who have first-morning urine dipstick ≥3+ on three or more consecutive days, 24-h PCR≥2.0g/g, or 24-h urine protein ≥ 50mg/kg, with or without edema after complete remission(KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases). It will be recorded as "1" when patients have a relapse, or as "0".
From admission day to 52 weeks
Cumulative prednisone dosage of each individual (milligrams per kilogram per year)
The total dosage of prednisone for each individual from the beginning to the end of the trial.
From admission day to 52 weeks
Assistente alla partecipazione
Criteri di eleggibilità

Età idonea
Bambino
Età minima
2 Years
Sessi idonei
Tutti
  1. New-onset idiopathic nephrotic syndrome
  2. Glomerular filtration rate (eGFR) ≥90 ml/min per 1.73 m2 at study entry.

  1. Glomerular hematuria: Urine red blood cell counts≥ 10/high power field(HP), ≥ 3 times within 2 weeks;
  2. Continuous hypocomplementaemia(< 0.9g/L) ;
  3. Repeated or persistent Hypertension(systolic and/or diastolic blood pressures measured greater than the 95th percent of blood pressure in children matching sex, age and height ≥3 different time points)
  4. Diagnosis of secondary NS, such as secondary to Systemic Lupus Erythematosus, Immunoglobulin A Vasculitis(IgAV), diabetes, Hepatitis B virus(HBV) infection, etc.
  5. Complicated with other kidney diseases, such as multiple renal cysts, ANCA vasculitis, urinary system abnormalities, etc;
  6. With a family history of nephrotic syndrome, chronic glomerulonephritis, uremia, or other kidney diseases;
  7. Other monogenic genetic diseases known as the effect the condition of nephrotic syndromes, such as Wilms' tumor 1(WT1), NPHS2, LAMB2, PLCE1, etc.
  8. Congenital or acquired immunodeficiency, or patients with active tuberculosis, active Epstein-Barr virus and cytomegalovirus(CMV), acute hepatitis B, hepatitis C, HIV infection, deep fungal infection or other active infections.
  9. Laboratory indicators were abnormal, such as moderate or severe neutropenia(≤1000/μL)， moderate or severe anemia(hemoglobin<9.0g/dL), Thrombocytopenia (platelet count<100* 10^12/L) or with abnormal hepatic function (Alaninetransaminase(ALT), aspartate Aminotransferase(AST) or bilirubin >2.5*upper limit of normal value and continue to increase for 2 weeks);
  10. Steroid or immunosuppressive medicine for other diseases within 3 months, such as cyclophosphamide, cyclosporine, tacrolimus, mycophenolate mofetil, tripterygium wilfordii, etc.
  11. With tumor, severe cardiac failure, severe hepatologic diseases, hematological diseases, or other severe system diseases.
  12. Patients who are known to be allergic to rituximab;
  13. History of transplantation, excluding cornea or hair transplantation;
  14. The attenuated live vaccine was inoculated within 1 month before enrollment;
  15. Patients who participated in other clinical trials within three months before enrollment;
  16. Patients are not suitable for inclusion in the trial by any investigator.
The Children's Hospital of Zhejiang University School of Medicine logoThe Children's Hospital of Zhejiang University School of Medicine
Parte responsabile dello studio
Mao Jianhua, Investigatore principale, Associate Dean, The Children's Hospital of Zhejiang University School of Medicine
Contatti principali dello studio
Contatto: Jianhua Mao, PHD.MD, 86057186670015, [email protected]
Contatto: Fei Liu, [email protected]
1 Centri dello studio in 1 paesi

Zhejiang

Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Li Qiu-Yu, Contatto, 17794588355, [email protected]
In arruolamento